Parkinsn's Email List Message
Posting to the Parkinsn List is a benefit of Subscription
Re: Depression, Psychosis, and Dementia in PD: 1997 EPDA Conference
A most excellent job, janet, but you're depressing me...
Only kidding,
Carole
P.S. On the bright side, last time I looked, I wasn't
demented or psychotic. I personally find the prospect of
psychiatric disability much scarier than physical
disability. But we Parkies have it all, don't we?
--- janet paterson <janet313@xxxxxxxxxxx> wrote:
> Depression, Psychosis, and Dementia in Parkinson's
> Disease,
> EPDA one day conference London 23rd-26th March, 1997
>
> Professor Jenner, Professor of Pharmacology, King's
> College Hospital, London
>
> Between 30 and 50% of Parkinson's patients experience
> depression; 20 to 40% dementia; 5 to 10% psychosis; and
> 15 to 20% drug induced psychosis. Clinicians often fail
> to deal with the neurobehavioural consequences of the
> disease. Treatment with dopamine agonists does not
> improve symptoms and may exacerbate other aspects of the
> disease; SSRI drugs can help. Dopaminergic cells
> throughout the brain are lost in the course of
> Parkinson's disease and are replaced by Lewy bodies, but
> it is not known if these changes produce the
> characteristic depression of the disease. Similarly,
> noradrenaline is also reduced by up to 50% in the limbic
> system and brainstem of sufferers and by over 75% in the
> frontal cortex: again, it is not known whether this
> causes dementia in patients; 5 HT reduction is associated
> with depression and psychosis, but is it cause or effect?
> Vascular disease and Alzheimer's disease symptoms may
> also be present, complicating the picture. What
> constitutes true Parkinson's!
> dis
> ease pathology?
>
> Professor Poewe, Department of Neurology, University
> Hospital, Innsbruck, Austria
>
> The prevalence of depression in Parkinson's disease
> averages about 40%, and may precede the appearance of
> motor symptoms in a third of patients, suggestive of the
> pre morbid personality theory of Parkinson's disease.
> There is no correlation between the degree of depression
> and severity of disease, but depression is a risk factor
> for cognitive decline and more rapid progression to
> disability. Treatment comprises psychosocial support;
> behavioural therapies; drugs: 'levodopa', dopamine
> agonists, 'deprenyl'; tricyclic antidepressants; 'SSRIs'
> and ECT or 'TMS'. The three step treatment comprises
> substitution of brain dopamine, followed by tricyclic
> antidepressants, and then an SSRI. Symptoms include: loss
> of interest and initiative; indecisiveness; guilt
> feelings; loss of self-esteem; suicidal thoughts (but
> rarely suicide itself, which distinguishes it from non
> Parkinson depression); poor concentration; anxiety and
> panic attacks; fatigue; disrupted sleep patterns.
>
> The areas of clinical overlap between motor symptoms,
> depression, and cognitive decline include reduced levels
> of: concentration and judgment; memory; psychomotor
> speed; cognitive processing speed; and higher levels of
> sleep disorders and mood swings. Patients often fail to
> discern voice tones and can no longer recognise humour.
>
> Professor Cote, Columbia Presbyterian Medical Center,
> Neurological Institute, New York, USA
>
> Depression may be present for many years before
> Parkinson's disease is diagnosed, but it is very
> difficult to recognise, because there are so many
> neurobehavioural changes in Parkinson's that could be
> mistaken for depression. The pre morbid personality
> traits include introversion, inflexibility, being a non
> drinker, having difficulty making sexual contacts, lack
> of competitive spirit, and inability to fantasise. An
> indicator of future disease in smokers may be giving up
> smoking some 5 to 15 years before diagnosis, because of
> the dependency of addictive drives on dopamine. The
> mental changes caused by Parkinson's disease include
> depression which often occurs early in the course of the
> disease. Treatment with tricyclics disguises Parkinson
> symptoms; SSRIs, on the other hand, can exacerbate
> symptoms. Depression may last from a few days to several
> weeks at a time. Symptoms of Parkinson's depression
> include: feelings of hopelessness/worthlessness; no
> interest in pleasure; guilt; su!
> icid
> al thoughts; fearfulness; reduced appetite; weight loss;
> disrupted sleep. Parkinson patients who are not depressed
> have significant reductions in serotonin metabolites, but
> in those who are depressed, the degree of reduction
> parallels the degree of depression. Treatment with
> levodopa can increase motor symptoms and provoke a
> withdrawal syndrome, which can itself generate depressive
> feelings. Low dose tricyclics with low levels of
> cholinergic action, SSRIs, ECT, psychotherapy, and light
> therapy are recommended.
>
> Dr Eric Wolters, Department of Neurology, Academic
> Hospital, Wrije Universiteit, Amsterdam, The Netherlands
>
> Degeneration of dopaminergic cells and their replacement
> by Lewy bodies in the brain tissue is a hallmark of
> Parkinson's disease. The process is diffuse, occurring in
> the brainstem, striatal, frontal, and limbic regions.
> Striatal changes produce motor symptoms, those in the
> frontal and limbic regions psychiatric symptoms,
> including dementia and psychosis. Drug treatments induce
> a range of psychiatric symptoms, as a result of their
> anticholinergic and dopaminergic actions.
> Neuropsychiatric side effects are seen in about 20% of
> non demented and in 80% of demented patients. Dose is
> thought to be an important factor. Delirium is more
> common in elderly patients because acetylcholine
> production reduces with age, especially in dementing
> illnesses. Efforts must be made to reduce sensory
> deprivation. Psychosis is characterised by delusions
> and/or hallucinations, which subsequently become
> extremely frightening. Mild neuroleptics or atypical
> neuroleptics are advised; dopamine agonists sh!
> ould
> be discontinued. Carers need to be informed about the
> consequences of drug treatment in Parkinson's disease.
>
> Professor Melamed, Department of Neurology, Rabin Medical
> Center, Tel Aviv University, Sackler School of Medicine,
> Israel
>
> Psychosis is the major non motor problem in Parkinson's
> disease, because it is a significant marker of disease
> deterioration and progression, and it's the most limiting
> factor in the treatment of motor symptoms in advanced
> disease. This is because of the requirement for high
> doses of levodopa and other drugs, long term use of which
> produce psychiatric symptoms. Psychosis is also the most
> common cause of admission of Parkinson patients into
> nursing homes. It may develop or worsen after infection,
> physical injury, surgery, or mental stress, and tends to
> be more common in older and demented patients. Several
> mechanisms are probably involved in its development. It
> is characterised by hallucinations, which at first are
> often benign, but these gradually become more frightening
> and disabling, resulting in aggression and severe
> agitation. Treatment has traditionally been to reduce
> levodopa and other antiparkinson drugs and substitute
> neuroleptics. However, these can produce a rapid an!
> d so
> metimes life threatening deterioration in motor symptoms.
> Ondansetron, an anti emetic used in the treatment of
> cancer, is well tolerated, with minimal side effects, but
> it is very expensive, and needs to be given in high
> doses.
>
> Professor Oertel, Neurology Clinic, Centre for Nervous
> Diseases, Philipps University, Marburg, Germany
>
> Dementia is acquired global impairment of higher cortical
> function, with a decline in memory, abstract thinking,
> and visuo spatial processing. It is a 'syndrome', with
> between 15 and 30% of patients with Parkinson's disease
> affected. Dementia can be part of depression, or, result
> from vascular disease or concurrent Alzheimer's disease:
> up to 20% of demented patients have both. About 5% of
> Parkinson patients also have Alzheimer's disease. Young
> onset Parkinson patients (35-40) rarely become demented,
> even at 65 and older, and Parkinson's is not a risk
> factor for dementia. Depression and dementia are,
> however, significantly correlated with Parkinson's
> disease. Dementia occurs when the neurofibrillary tangles
> strangle the nuclei of nerve cells in the brain, and
> plaques develop in the cortical areas. It begins in the
> temporal lobe, with a lesion the size of a 50p coin, and
> spreads. Dopamine levels are reduced as are levels of
> acetylcholine, hallmarks of both Alzheimer's and Parkin!
> son'
> s disease, but although patients with Apo E deposits
> develop cognitive impairments earlier than those without,
> these deposits are only a risk factor for Alzheimer's
> disease. Symptoms include apraxia, aphasia, personality
> changes, compromised short term memory, confusion,
> hallucinations, bradyphrenia and depression. Treatment is
> limited and may exacerbate other Parkinson's symptoms.
> Behavioural and occupational therapies, and psychosocial
> support are vital for the patient and his/her family.
>
> Professor Ellgring, Institute for Psychology, University
> of Wuerzburg, Germany
>
> Depression, dementia, and psychosis stretch the emotional
> resources of the families and carers of Parkinson's
> patients. Demands for care and social interaction are
> increased; there are adverse effects on health; stress
> increases; social isolation may result; and there are
> financial implications. These are compounded when the
> carer is elderly. The major concerns for carers of
> patients with Parkinson's and Alzheimer's focus on
> worries about the future, fear of leaving the patient
> unattended, and being misunderstood by the family. Carers
> are conflicted over encouraging independence in the
> patient; having to assume all the responsibility;
> restrictions on their own lifestyle; and feeling
> impatient and angry. Mental health problems among carers
> are common, and often become worse when the patient is
> transferred to a nursing home because of the attendant
> guilt, loneliness, and loss of identity. Sleep disorders
> and somatic illness are also common. There are times when
> both patient and !
>
=== message truncated ===
__________________________________________________
Do You Yahoo!?
Yahoo! Shopping - Thousands of Stores. Millions of Products.
Parkinsn's Archive Treasures Doctors, students, patients and caregivers find current Parkinson's information such as the Algorithm, Caregivers Handbook, and talks by respected Movement Disorder Specialists.
Mail converted by MHonArc
2.6.10
Site Hosting donated by He.net
&
Grant from The Parkinson Alliance